NeuroPace (NPCE) Projected to Post Earnings on Tuesday

NeuroPace (NASDAQ:NPCE) is projected to announce its Q4 2025 results after the market closes on Tuesday, March 3rd. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $24.7910 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 4:30 PM ET.

NeuroPace Stock Performance

NASDAQ NPCE opened at $14.58 on Friday. The firm has a market capitalization of $485.66 million, a P/E ratio of -19.18 and a beta of 1.85. NeuroPace has a 1-year low of $7.56 and a 1-year high of $18.98. The company has a debt-to-equity ratio of 3.17, a current ratio of 4.86 and a quick ratio of 3.94. The business’s 50-day simple moving average is $15.78 and its 200-day simple moving average is $13.16.

Analysts Set New Price Targets

A number of brokerages have weighed in on NPCE. Leerink Partners reaffirmed an “outperform” rating and set a $19.00 price target on shares of NeuroPace in a research report on Wednesday, November 5th. JPMorgan Chase & Co. raised their target price on shares of NeuroPace from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. HC Wainwright lifted their target price on shares of NeuroPace from $18.00 to $19.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeuroPace in a research report on Monday, December 29th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $16.00 price objective on shares of NeuroPace in a research report on Wednesday, November 5th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $18.67.

Institutional Trading of NeuroPace

Several large investors have recently modified their holdings of the business. Legal & General Group Plc lifted its stake in shares of NeuroPace by 86.0% in the second quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock worth $30,000 after acquiring an additional 1,239 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of NeuroPace in the 2nd quarter valued at approximately $35,000. Quarry LP raised its position in shares of NeuroPace by 94.9% in the 3rd quarter. Quarry LP now owns 3,845 shares of the company’s stock valued at $40,000 after purchasing an additional 1,872 shares in the last quarter. New York State Common Retirement Fund boosted its stake in shares of NeuroPace by 755.6% during the 4th quarter. New York State Common Retirement Fund now owns 7,700 shares of the company’s stock valued at $119,000 after buying an additional 6,800 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of NeuroPace by 60.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,160 shares of the company’s stock worth $147,000 after buying an additional 4,972 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

NeuroPace Company Profile

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.